Insider Selling: MabVax Therapeutics Holdings, Inc. (MBVX) CEO Sells 18,582 Shares of Stock

MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) CEO John David Hansen sold 18,582 shares of the firm’s stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $0.96, for a total value of $17,838.72. Following the transaction, the chief executive officer now owns 788,683 shares in the company, valued at approximately $757,135.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

John David Hansen also recently made the following trade(s):

  • On Wednesday, January 10th, John David Hansen sold 110,093 shares of MabVax Therapeutics stock. The stock was sold at an average price of $0.96, for a total value of $105,689.28.

MabVax Therapeutics Holdings, Inc. (MBVX) opened at $0.90 on Tuesday. The company has a current ratio of 0.54, a quick ratio of 0.54 and a debt-to-equity ratio of 0.80. MabVax Therapeutics Holdings, Inc. has a 1-year low of $0.43 and a 1-year high of $3.59. The stock has a market capitalization of $18.46, a PE ratio of -0.25 and a beta of 1.52.

MabVax Therapeutics (NASDAQ:MBVX) last issued its earnings results on Tuesday, November 7th. The company reported ($0.54) earnings per share (EPS) for the quarter. sell-side analysts expect that MabVax Therapeutics Holdings, Inc. will post -3.01 EPS for the current year.

A hedge fund recently bought a new stake in MabVax Therapeutics stock. Cambridge Investment Research Advisors Inc. bought a new position in shares of MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 2,495,203 shares of the company’s stock, valued at approximately $1,622,000. Cambridge Investment Research Advisors Inc. owned about 12.33% of MabVax Therapeutics at the end of the most recent quarter. 12.87% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at

About MabVax Therapeutics

MabVax Therapeutics Holdings, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers.

Insider Buying and Selling by Quarter for MabVax Therapeutics (NASDAQ:MBVX)

Receive News & Ratings for MabVax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MabVax Therapeutics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit